Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine after myocardial infarction for left ventricular function
IRCT20260126068670N1Phase 3Recruiting
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) and acute ST-segment elevation myocardial infarction (STEMI) comparing Ranolazine plus standard treatment with Placebo plus standard treatment (2 arms). Primary endpoint: Change in left ventricular ejection fraction. Started Jan 2026; status: recruiting.
02
Drugs
ranolazine
03
Conditions
myocardial infarction (MI)acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on IRCT20260126068670N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260126068670N1.